Transzumab 440

Transzumab 440 mg Injection
Transzumab 440 mg Injection (Trastuzumab) is a recombinant humanized monoclonal antibody used in targeted therapy for HER2-positive cancers. It specifically targets the HER2 receptor on cancer cells, inhibiting tumor cell proliferation and enhancing immune-mediated cancer cell destruction. Transzumab 440 mg is widely used in global oncology treatment protocols.
Product Details
Brand Name: Transzumab
Generic Name: Trastuzumab
Strength: 440 mg
Dosage Form: Injection (Sterile lyophilized powder for reconstitution)
Route of Administration: Intravenous (IV infusion)
Therapeutic Class: Monoclonal Antibody / Targeted Anticancer Agent
Indications
Transzumab 440 mg Injection is indicated for the treatment of:
HER2-positive early and metastatic breast cancer
HER2-positive metastatic gastric or gastroesophageal junction cancer
(HER2 overexpression must be confirmed before initiating therapy)
Mechanism of Action
Trastuzumab selectively binds to the HER2 receptor on tumor cells, blocking HER2-mediated signaling pathways. This inhibits cancer cell growth and activates antibody-dependent cell-mediated cytotoxicity (ADCC).
Key Benefits
Targeted therapy for HER2-positive cancers
Clinically proven to improve survival outcomes
Can be used as monotherapy or in combination chemotherapy
Established and trusted global oncology standard
Dosage & Administration
Dosage and infusion schedule are determined by the oncologist based on patient body weight, clinical condition, and treatment protocol. Administration must be performed under strict medical supervision.
Storage Conditions
Store at 2°C to 8°C (Refrigerated)
Do not freeze
Protect from light
Precautions
For hospital and oncology center use only
Regular cardiac monitoring is recommended
Use with caution in patients with existing cardiac disorders